全文获取类型
收费全文 | 4301篇 |
免费 | 333篇 |
国内免费 | 9篇 |
专业分类
耳鼻咽喉 | 54篇 |
儿科学 | 124篇 |
妇产科学 | 105篇 |
基础医学 | 744篇 |
口腔科学 | 137篇 |
临床医学 | 511篇 |
内科学 | 804篇 |
皮肤病学 | 81篇 |
神经病学 | 309篇 |
特种医学 | 149篇 |
外科学 | 594篇 |
综合类 | 50篇 |
一般理论 | 5篇 |
预防医学 | 376篇 |
眼科学 | 60篇 |
药学 | 276篇 |
中国医学 | 2篇 |
肿瘤学 | 262篇 |
出版年
2022年 | 38篇 |
2021年 | 61篇 |
2020年 | 47篇 |
2019年 | 76篇 |
2018年 | 80篇 |
2017年 | 75篇 |
2016年 | 90篇 |
2015年 | 77篇 |
2014年 | 107篇 |
2013年 | 176篇 |
2012年 | 229篇 |
2011年 | 213篇 |
2010年 | 112篇 |
2009年 | 95篇 |
2008年 | 206篇 |
2007年 | 186篇 |
2006年 | 175篇 |
2005年 | 182篇 |
2004年 | 199篇 |
2003年 | 175篇 |
2002年 | 160篇 |
2001年 | 140篇 |
2000年 | 139篇 |
1999年 | 127篇 |
1998年 | 53篇 |
1997年 | 37篇 |
1996年 | 47篇 |
1995年 | 44篇 |
1994年 | 34篇 |
1993年 | 32篇 |
1992年 | 87篇 |
1991年 | 76篇 |
1990年 | 90篇 |
1989年 | 89篇 |
1988年 | 81篇 |
1987年 | 65篇 |
1986年 | 65篇 |
1985年 | 74篇 |
1984年 | 42篇 |
1983年 | 46篇 |
1982年 | 34篇 |
1981年 | 32篇 |
1979年 | 29篇 |
1978年 | 37篇 |
1977年 | 35篇 |
1976年 | 31篇 |
1975年 | 39篇 |
1974年 | 32篇 |
1973年 | 32篇 |
1972年 | 33篇 |
排序方式: 共有4643条查询结果,搜索用时 15 毫秒
81.
82.
Warren Kati Gennadiy Koev Michelle Irvin Jill Beyer Yaya Liu Preethi Krishnan Thomas Reisch Rubina Mondal Rolf Wagner Akhteruzzaman Molla Clarence Maring Christine Collins 《Antimicrobial agents and chemotherapy》2015,59(3):1505-1511
Dasabuvir (ABT-333) is a nonnucleoside inhibitor of the RNA-dependent RNA polymerase encoded by the hepatitis C virus (HCV) NS5B gene. Dasabuvir inhibited recombinant NS5B polymerases derived from HCV genotype 1a and 1b clinical isolates, with 50% inhibitory concentration (IC50) values between 2.2 and 10.7 nM, and was at least 7,000-fold selective for the inhibition of HCV genotype 1 polymerases over human/mammalian polymerases. In the HCV subgenomic replicon system, dasabuvir inhibited genotype 1a (strain H77) and 1b (strain Con1) replicons with 50% effective concentration (EC50) values of 7.7 and 1.8 nM, respectively, with a 13-fold decrease in inhibitory activity in the presence of 40% human plasma. This level of activity was retained against a panel of chimeric subgenomic replicons that contained HCV NS5B genes from 22 genotype 1 clinical isolates from treatment-naive patients, with EC50s ranging between 0.15 and 8.57 nM. Maintenance of replicon-containing cells in medium containing dasabuvir at concentrations 10-fold or 100-fold greater than the EC50 resulted in selection of resistant replicon clones. Sequencing of the NS5B coding regions from these clones revealed the presence of variants, including C316Y, M414T, Y448C, Y448H, and S556G, that are consistent with binding to the palm I site of HCV polymerase. Consequently, dasabuvir retained full activity against replicons known to confer resistance to other polymerase inhibitors, including the S282T variant in the nucleoside binding site and the M423T, P495A, P495S, and V499A single variants in the thumb domain. The use of dasabuvir in combination with inhibitors targeting HCV NS3/NS4A protease (ABT-450 with ritonavir) and NS5A (ombitasvir) is in development for the treatment of HCV genotype 1 infections. 相似文献
83.
Olivera Grbovic-Huezo Kenneth L. Pitter Nicolas Lecomte Joseph Saglimbeni Gokce Askan Matilda Holm Jerry P. Melchor Rohit Chandwani Suhasini Joshi Caj Haglund Christine A. Iacobuzio-Donahue Gabriela Chiosis Tuomas Tammela Steven D. Leach 《Proceedings of the National Academy of Sciences of the United States of America》2020,117(48):30670
84.
85.
Carotid artery intima-media thickness in Finnish families with familial combined hyperlipidemia 总被引:3,自引:0,他引:3
BACKGROUND: Familial combined hyperlipidemia (FCHL) is the most common hereditary lipid disorder that predisposes the patients to premature coronary heart disease. Members of FCHL families are categorised as affected or unaffected according to serum lipid levels. This study is aimed to evaluate whether there is a difference in carotid artery wall thickness between asymptomatic FCHL family members who are affected and those who are unaffected according to the currently used lipid criteria. METHODS AND RESULTS: Carotid artery ultrasonography with intima-media thickness (IMT) measurements was performed for 148 members of 39 Finnish FCHL families. Study subjects who had no history of coronary heart disease or stroke were divided into two groups according to their serum total cholesterol and/or triglyceride levels. The average carotid IMT of the affected subjects (0.75+/-0.15 mm) was not significantly different from that of their unaffected relatives (0.73+/-0.13 mm), P=0.90. In multivariate analysis, age, gender, and pulse pressure, but no lipid variables, contributed significantly to the variation of carotid IMT. CONCLUSIONS: The IMT findings in FCHL family members indicate that the current lipid criteria alone are of limited value in predicting long-term risk of cardiovascular disease in asymptomatic members of FCHL families. 相似文献
86.
87.
Ekaterina Klimatcheva Tracy Pandina Christine Reilly Sebold Torno Holm Bussler Maria Scrivens Alan Jonason Crystal Mallow Michael Doherty Mark Paris Ernest S Smith Maurice Zauderer 《BMC immunology》2015,16(1)
Background
Homeostatic B Cell-Attracting chemokine 1 (BCA-1) otherwise known as CXCL13 is constitutively expressed in secondary lymphoid organs by follicular dendritic cells (FDC) and macrophages. It is the only known ligand for the CXCR5 receptor, which is expressed on mature B cells, follicular helper T cells (Tfh), Th17 cells and regulatory T (Treg) cells. Aberrant expression of CXCL13 within ectopic germinal centers has been linked to the development of autoimmune disorders (e.g. Rheumatoid Arthritis, Multiple Sclerosis, Systemic Lupus Erythematosis). We, therefore, hypothesized that antibody-mediated disruption of the CXCL13 signaling pathway would interfere with the formation of ectopic lymphoid follicles in the target organs and inhibit autoimmune disease progression. This work describes pre-clinical development of human anti-CXCL13 antibody MAb 5261 and includes therapeutic efficacy data of its mouse counterpart in murine models of autoimmunity.Results
We developed a human IgG1 monoclonal antibody, MAb 5261 that specifically binds to human, rodent and primate CXCL13 with an affinity of approximately 5 nM and is capable of neutralizing the activity of CXCL13 from these various species in in vitro functional assays. For in vivo studies we have engineered a chimeric antibody to contain the same human heavy and light chain variable genes along with mouse constant regions. Treatment with this antibody led to a reduction in the number of germinal centers in mice immunized with 4-Hydroxy-3-nitrophenylacetyl hapten conjugated to Keyhole Limpet Hemocyanin (NP-KLH) and, in adoptive transfer studies, interfered with the trafficking of B cells to the B cell areas of mouse spleen. Furthermore, this mouse anti-CXCL13 antibody demonstrated efficacy in a mouse model of Rheumatoid arthritis (Collagen-Induced Arthritis (CIA)) and Th17-mediated murine model of Multiple Sclerosis (passively-induced Experimental Autoimmune Encephalomyelitis (EAE)).Conclusions
We developed a novel therapeutic antibody targeting CXCL13-mediated signaling pathway for the treatment of autoimmune disorders. 相似文献88.
I. H. Lambert D. M. Kristensen J. B. Holm O. H. Mortensen 《Acta physiologica (Oxford, England)》2015,213(1):191-212
Taurine is often referred to as a semi‐essential amino acid as newborn mammals have a limited ability to synthesize taurine and have to rely on dietary supply. Taurine is not thought to be incorporated into proteins as no aminoacyl tRNA synthetase has yet been identified and is not oxidized in mammalian cells. However, taurine contributes significantly to the cellular pool of organic osmolytes and has accordingly been acknowledged for its role in cell volume restoration following osmotic perturbation. This review describes taurine homeostasis in cells and organelles with emphasis on taurine biophysics/membrane dynamics, regulation of transport proteins involved in active taurine uptake and passive taurine release as well as physiological processes, for example, development, lung function, mitochondrial function, antioxidative defence and apoptosis which seem to be affected by a shift in the expression of the taurine transporters and/or the cellular taurine content. 相似文献
89.